Pharmacoeconomic evaluation of penpulimab in first-line treatment of advanced squamous non-small-cell lung cancer

HU Dongxue; ZHENG Ying; GAO Qian; HU Shiyuan; WANG Danfeng; YU Fangzhu; DONG Lei

doi:10.6039/j.issn.1001-0408.2025.11.13

您当前的位置：

首页 >

文章列表页 >

Pharmacoeconomic evaluation of penpulimab in first-line treatment of advanced squamous non-small-cell lung cancer

更新时间：2025-06-09

- Pharmacoeconomic evaluation of penpulimab in first-line treatment of advanced squamous non-small-cell lung cancer
- ZHONGGUO YAOFANG Vol. 36, Issue 11, Pages: 1364-1369(2025)
- 作者机构：
  
  1.河北医科大学药学院，石家庄　050017
  2.河北医科大学第四医院药学部，石家庄　050011
  3.河北省儿童医院药学部，石家庄　050031
- 作者简介：
- 基金信息：
- DOI：10.6039/j.issn.1001-0408.2025.11.13
  CLC： R956;R979.1
- Received：06 December 2024，
  
  Revised：12 May 2025，
  
  Accepted：13 May 2025，
  
  Published：15 June 2025
- 稿件说明：
移动端阅览
胡冬雪,郑颖,高倩等.派安普利单抗一线治疗晚期鳞状非小细胞肺癌的药物经济学评价 ^Δ[J].中国药房,2025,36(11):1364-1369.

HU Dongxue,ZHENG Ying,GAO Qian,et al.Pharmacoeconomic evaluation of penpulimab in first-line treatment of advanced squamous non-small-cell lung cancer[J].ZHONGGUO YAOFANG,2025,36(11):1364-1369.
胡冬雪,郑颖,高倩等.派安普利单抗一线治疗晚期鳞状非小细胞肺癌的药物经济学评价 ^Δ[J].中国药房,2025,36(11):1364-1369. DOI： 10.6039/j.issn.1001-0408.2025.11.13.

HU Dongxue,ZHENG Ying,GAO Qian,et al.Pharmacoeconomic evaluation of penpulimab in first-line treatment of advanced squamous non-small-cell lung cancer[J].ZHONGGUO YAOFANG,2025,36(11):1364-1369. DOI： 10.6039/j.issn.1001-0408.2025.11.13.

摘要

目的

评价派安普利单抗联合化疗方案一线治疗晚期鳞状非小细胞肺癌（以下简称“肺鳞癌”）的经济性。

方法

从我国卫生体系角度出发，运用成本-效用分析法评估派安普利单抗联合化疗（紫杉醇+卡铂）方案相较于标准化疗（紫杉醇+卡铂）方案一线治疗晚期肺鳞癌的经济性。使用R语言构建一个三健康状态Markov模型，模型中所需的临床数据提取自AK105-302研究，成本和效用来自开放数据库和已发表的文献。效用指标为质量调整生命年（QALY），意愿支付（WTP）阈值为2024年我国人均国内生产总值（GDP）的3倍，即287 247元/QALY。通过比较两种方案的增量成本-效果比（ICER）与WTP阈值的大小评估方案的经济性；使用单因素敏感性分析和概率敏感性分析验证基础分析的稳健性。

结果

派安普利单抗联合化疗方案较标准化疗方案增加了0.73 QALY，但同时成本增加150 681.93元，ICER为206 413.60元/QALY。单因素敏感性分析显示，无进展生存（PFS）状态的效用值对ICER的影响最大。概率敏感性分析显示，WTP阈值为3倍的2024年我国人均GDP时，派安普利单抗联合化疗方案具有经济性的概率为98.80%；但当WTP阈值降低为1倍我国人均GDP时，派安普利单抗联合化疗方案具有经济性的概率＜0.01%。

结论

对于晚期肺鳞癌，当WTP阈值为3倍的2024年我国人均GDP时，派安普利单抗联合化疗是一种具有经济性的一线治疗方案。

Abstract

OBJECTIVE

To estimate the cost-effectiveness of penpulimab combined with chemotherapy versus chemotherapy alone in first-line treatment of advanced squamous non-small-cell lung cancer （sq-NSCLC）.

METHODS

From the perspective of Chinese health system， cost-utility analysis was used to evaluate the cost-effectiveness of penpulimab combined with chemotherapy（paclitaxel + carboplatin） versus chemotherapy （paclitaxel + carboplatin） in first-line treatment of sq-NSCLC. A three-health states Markov model was constructed with R packages， and clinical data used in the model were derived from the AK105-302 clinical trial. Costs and utilities were collected from the open-access database and published literature. The quality-adjusted life-years （QALY） was used as the utility index， and the willingness-to-pay （WTP） threshold was set at three times China’s per capita GDP in 2024， equivalent to 287 247 yuan/QALY. The cost-effectiveness of the schemes was evaluated by comparing the incremental cost-utility ratios （ICER） of the two schemes with the WTP threshold. One-way sensitivity analysis and probabilistic sensitivity analysis （PSA） were used to verify the stability of the basic analysis results.

RESULTS

Compared with chemotherapy， penpulimab combined with chemotherapy increased 0.73 QALY with an incremental cost of 150 681.93 yuan， and the ICER was 206 413.60 yuan/QALY. One-way sensitivity analysis showed that the utility of progression-free survival was the most sensitive factor on ICERs. At the WTP threshold of 3 times China’s per capita GDP， the economic probability of this scheme was 98.80%. At the WTP threshold of 1 times China’s per capita GDP， the probability of ICER being cost-effective was less than 0.01%.

CONCLUSIONS

For patients with advanced sq-NSCLC， penpulimab combined with chemotherapy is a cost-effective first-line treatment option when WTP threshold is 3 times China’s per capita GDP.

关键词

Keywords

references

郑荣寿，陈茹，韩冰峰，等 . 2022年中国恶性肿瘤流行情况分析 [J ] . 中华肿瘤杂志， 2024 ， 46 （ 3 ）： 221 - 231 .

LEITER A ， VELUSWAMY R R ， WISNIVESKY J P . The global burden of lung cancer：current status and future trends [J ] . Nat Rev Clin Oncol ， 2023 ， 20 （ 9 ）： 624 - 639 .

WANG W ， LIU H ， LI G L . What’s the difference between lung adenocarcinoma and lung squamous cell carcinoma? Evidence from a retrospective analysis in a cohort of Chinese patients [J ] . Front Endocrinol （Lausanne）， 2022 ， 13 ： 947443 .

SOCINSKI M A ， OBASAJU C ， GANDARA D ， et al . Current and emergent therapy options for advanced squamous cell lung cancer [J ] . J Thorac Oncol ， 2018 ， 13 （ 2 ）： 165 - 183 .

LAU S C M ， PAN Y W ， VELCHETI V ， et al . Squamous cell lung cancer：current landscape and future therapeutic options [J ] . Cancer Cell ， 2022 ， 40 （ 11 ）： 1279 - 1293 .

国家卫生健康委办公厅 . 关于印发原发性肺癌等18个肿瘤诊疗规范（2018年版）的通知 [EB/OL ] .（ 2018-12-13 ）[ 2024-11-10 ] . http：//www.nhc.gov.cn/yzygj/s7659/201812/b21802b199814ab7b1219b87de0cae51.shtml http://www.nhc.gov.cn/yzygj/s7659/201812/b21802b199814ab7b1219b87de0cae51.shtml .

LI X L ， SHAO C S ， SHI Y F ， et al . Lessons learned from the blockade of immune checkpoints in cancer immunotherapy [J ] . J Hematol Oncol ， 2018 ， 11 （ 1 ）： 31 .

DHILLON S . Penpulimab：first approval [J ] . Drugs ， 2021 ， 81 （ 18 ）： 2159 - 2166 .

ZHONG H ， SUN S J ， CHEN J H ， et al . First-line penpulimab combined with paclitaxel and carboplatin for metastatic squamous non-small-cell lung cancer in China （AK105-302）：a multicentre，randomised，double-blind，placebo-controlled phase 3 clinical trial [J ] . Lancet Respir Med ， 2024 ， 12 （ 5 ）： 355 - 365 .

HAN B ， CHEN J ， WANG Z ， et al . Penpulimab in combination with anlotinib as first-line treatment in advanced nonsquamous non-small-cell lung cancer [J ] . J Clin Oncol ， 2021 ， 39 （ 15 ）： e21072 - e21072 .

中国医师协会肿瘤医师分会，中国医疗保健国际交流促进会肿瘤内科分会 . Ⅳ期原发性肺癌中国治疗指南：2023年版 [J ] . 中国综合临床， 2023 ， 39 （ 3 ）： 161 - 190 .

中国临床肿瘤学会指南工作委员会 . 中国临床肿瘤学会（CSCO）免疫检查点抑制剂临床应用指南：2024 [M ] . 北京：人民卫生出版社， 2024 ： 54 .

中华医学会肿瘤学分会，中华医学会杂志社 . 中华医学会肺癌临床诊疗指南： 2023版 [J ] . 中华肿瘤杂志， 2023 ， 45 （ 7 ）： 539 - 574 .

刘国恩 . 中国药物经济学评价指南2020 [M ] . 北京：中国市场出版社， 2020 ： 27 - 115 .

刘家一，李伟 . R语言实例解析肿瘤治疗药物经济学评价的分区生存模型 [J ] . 数理医药学杂志， 2024 ， 37 （ 4 ）： 240 - 251 .

GOULART B ， RAMSEY S . A trial-based assessment of the cost-utility of bevacizumab and chemotherapy versus chemotherapy alone for advanced non-small cell lung cancer [J ] . Value Health ， 2011 ， 14 （ 6 ）： 836 - 845 .

RUI M J ， FEI Z Y ， WANG Y C ， et al . Cost-effectiveness analysis of sintilimab + chemotherapy versus camrelizumab + chemotherapy for the treatment of first-line locally advanced or metastatic nonsquamous NSCLC in China [J ] . J Med Econ ， 2022 ， 25 （ 1 ）： 618 - 629 .

SHAO T H ， REN Y N ， ZHAO M Y ， et al . Cost-effectiveness analysis of camrelizumab plus chemotherapy as first-line treatment for advanced squamous NSCLC in China [J ] . Front Public Health ， 2022 ， 10 ： 912 - 921 .

刘国强，康朔，王欣晨 . 帕博利珠单抗一线治疗PD-L1高表达的晚期非小细胞肺癌的药物经济学评价 [J ] . 中国药房， 2021 ， 32 （ 11 ）： 1351 - 1356 .

齐冉，聂旭阳，刘旭婷，等 . 斯鲁利单抗联合化疗方案一线治疗广泛期小细胞肺癌的药物经济学评价 [J ] . 中国药房， 2023 ， 34 （ 11 ）： 1368 - 1373 .

NAFEES B ， LLOYD A J ， DEWILDE S ， et al . Health state utilities in non-small cell lung cancer：an international study [J ] . Asia Pac J Clin Oncol ， 2017 ， 13 （ 5 ）： e195 - e203 .

ALLEMANI C ， WEIR H K ， CARREIRA H ， et al . Global surveillance of cancer survival 1995-2009：analysis of individual data for 25 676 887 patients from 279 population-based registries in 67 countries （CONCORD-2） [J ] . Lancet ， 2015 ， 385 （ 9972 ）： 977 - 1010 .

ALLEMANI C ， MATSUDA T ， DI CARLO V ， et al . Global surveillance of trends in cancer survival 2000-14 （CONCORD-3）：analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries [J ] . Lancet ， 2018 ， 391 （ 10125 ）： 1023 - 1075 .

CARLISLE J W ， STEUER C E ， OWONIKOKO T K ， et al . An update on the immune landscape in lung and head and neck cancers [J ] . CA Cancer J Clin ， 2020 ， 70 （ 6 ）： 505 - 517 .

XU L Z ， CHEN M S ， ANGELL B ， et al . Establishing cost-effectiveness threshold in China：a community survey of willingness to pay for a healthy life year [J ] . BMJ Glob Health ， 2024 ， 9 （ 1 ）： e013070 .

ZHAO Z X ， YANG Y ， WU W J ， et al . Willingness to pay for cancer prevention versus treatment in China：implications for cost-effectiveness threshold [J ] . Expert Rev Pharmacoecon Outcomes Res ， 2024 ， 24 （ 1 ）： 155 - 160 .

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Cost-utility analysis of tislelizumab in the second-line treatment of advanced or metastatic esophageal squamous cell carcinoma

Cost-effectiveness of second-line treatment of advanced gastrointestinal stromal tumors with ripretinib versus sunitinib

Pharmacoeconomic evaluation of trastuzumab biosimilars versus original drug in the treatment of recurrent/metastatic HER-2 positive breast cancer

Study on pharmacoeconomic evaluation of vericiguat in the treatment of heart failure with reduced ejection fraction

Cost-utility analysis of tislelizumab monotherapy for second-line treatment of advanced or metastatic esophageal squamous cell carcinoma

Related Author

SONG Zehua

ZHU Xiaohong

WANG Ruixue

SHI Zhao

WANG Kaixuan

DOU Lei

LI Shunping

LIU Shixian

Related Institution

Centre for Health Management and Policy Research， School of Public Health， Cheeloo College of Medicine， Shandong University

NHC Key Lab of Health Economics and Policy Research （Shandong University）

Center for Health Preference Research， Shandong University

Key Speciality of Clinical Pharmacy， the First Affiliated Hospital of Guangdong Pharmaceutical University

Dept. of Pharmacy， Harbin Medical University Cancer Hospital

Address：8th Floor, Sihuan Building, No. 129 Daping Main Street, Yuzhong District, Chongqing, China Postal code：400042
Technical support is provided by Beijing Founder Electronics co., LTD 渝ICP备15012710号公网安备50010302001817
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰